News

AAV Immunosuppressants Can Increase Risk for COVID-19 Reinfection

A case of reinfection with COVID-19 has been reported in a patient who received immunosuppressive treatment for ANCA-associated vasculitis (AAV), which was linked to her first infection. Before her second infection, the 70-year-old African woman was given prednisolone and cyclophosphamide to combat AAV-associated kidney damage that had occurred after her…

CT Scan May Help Predict Prognosis of AAV With Lung Involvement

Classifying pulmonary manifestations in people with ANCA-associated vasculitis (AAV) with lung symptoms can help predict disease outcomes and determine which patients should receive more intensive treatment, a study from China suggests. For example, patients showing bleeding into the lungs (alveolar hemorrhage) in their computed tomography (CT) scan of the…

Tavneos Approved in EU as Oral Add-on Treatment for MPA, GPA

The European Commission has approved Tavneos (avacopan) as an add-on therapy for adults with severe granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) — the two main types of ANCA-associated vasculitis (AAV). Following the expected launch this year, Tavneos will be the first available oral therapy for…

Immunosuppressant MMF More Effective in Cases With Kidney Issues

Mycophenolate mofetil (MMF), an immunosuppressant, may sustain remission more efficiently than other therapies in ANCA-associated vasculitis (AAV) patients who have kidney symptoms, a review of clinical trials found. The findings showed that, in clinical trials enrolling only patients with kidney involvement, more than 90% were estimated to maintain…

COVID-19 Exposure Could Trigger AAV, Case Report Suggests

ANCA-associated vasculitis (AAV) may be a rare complication of exposure to COVID-19 proteins, either through infection or vaccination, a report covering two women suggests. Both were diagnosed early and improved with supportive care and immunosuppressive therapy, the researchers noted. “This adverse event appears to be a very rare complication…

PR3-ANCA Antibodies Tied to More Relapses in EGPA Patients

People with eosinophilic granulomatosis with polyangiitis (EGPA) who carry antibodies against the proteinase 3 (PR3) protein have more frequent relapses and a shorter time to relapse or death than patients without such antibodies, a South Korean study shows. These findings highlight the need to look for the presence of…

Moderna COVID-19 Vaccine May Trigger AAV-linked Kidney Damage

Kidney inflammation associated with ANCA-associated vasculitis (AAV) was recently reported in a man following his second dose of the Moderna COVID-19 vaccine. While cases of AAV have been described after COVID-19 infection and vaccination, this is only the third case of AAV-related kidney inflammation, with antibodies against the proteinase…